Tumour genetic / molecular testing
Laboratory tests on a sample of the cancer (or sometimes blood) to look for genetic and molecular changes that help confirm the diagnosis and guide which treatments are most likely to help.
✓ Medically reviewed by a GMC-registered consultant · last reviewed September 2026 · next review September 2027 · how we review
In short
- It tests the cancer for genetic and molecular changes to help confirm the diagnosis and pick treatments most likely to help.
- Most tests look at changes in the cancer itself (somatic), not inherited genes — but a result can sometimes lead to a separate inherited-risk test with counselling.
- It gives information, not treatment: a result can guide choices but cannot guarantee a treatment will work.
- Sometimes there is not enough tissue, the result is inconclusive, or no targeted option is found — so ask what each possible result would change.
A plain-English summary. The detail — including risks and recovery — is below.
At a glance
A general guide. Your specialist will give you advice for your situation.
Can confirm or refine exactly what type of cancer you have.
When the result would not change the treatment plan for that cancer and stage.
If tissue already exists, nothing further is needed. If a new biopsy is required, follow the recovery advice for that procedure.
A clinic appointment where an oncologist explains the result and what it changes.
If tissue already exists, nothing further is needed. If a new biopsy is required, follow the recovery advice for...
Results typically take from a few days to about three weeks. It is normal to feel anxious during this wait.
Findings are usually discussed at an MDT, then explained to you by your oncologist, including how they affect your...
You may be offered a repeat test, a different test, or a further biopsy. Your team will explain why.
What is tumour genetic / molecular testing?
Tumour genetic or molecular testing looks at a sample of the cancer in the laboratory to find changes in its genes and proteins. These changes are sometimes called biomarkers. The aim is to understand what is driving that particular cancer so the team can choose the treatment most likely to help — and avoid treatments unlikely to work.
Most of these tests are 'somatic' tests. That means they look at changes that happened in the cancer cells during life. They are not the same as inherited (germline) genetic tests that look at genes you were born with and could pass on, although sometimes a tumour result prompts a separate inherited-risk test with proper genetic counselling. Your team will be clear about which kind of test is being done.
The sample usually comes from a biopsy or from tissue already removed at an operation. Increasingly, some changes can be looked for in a blood sample (a 'liquid biopsy') that picks up tumour DNA in the blood, which can be useful when tissue is limited.
Molecular testing is a source of information, not a treatment. A result can confirm or refine the diagnosis, show whether a targeted drug or immunotherapy might help, and sometimes give a sense of how the cancer may behave. It cannot, on its own, tell you that treatment will work or predict exactly what will happen.
Types, options & approaches
There may be different ways to do this. The right approach depends on the clinical question and your circumstances.
Tissue sample compared with blood (liquid biopsy)
| Point | Tissue sample | Blood (liquid biopsy) |
|---|---|---|
| How it is taken | From a biopsy or surgery | A blood sample |
| Information | Detailed, well-established | Useful but may miss some changes |
| When it helps | The usual first choice | When tissue is limited or repeat sampling is hard |
| A negative result | Generally reliable for what was tested | Does not always rule a change out |
The two can be complementary. Your team chooses based on the cancer type, how much tissue is available and what decision the result needs to inform.
Preparing for your test
- Ask what the test is looking for and which treatment decision it will inform.
- Check whether a new biopsy is needed or whether tissue already removed can be used.
- Tell your team about previous biopsies, operations or test results, which may save another procedure.
- Ask roughly how long results will take, as this can affect when treatment starts.
- Ask whether the test could reveal an inherited risk, and what support would follow if so.
- Discuss what happens to your sample and data, and consent for any research use.
- If a biopsy is needed to get the sample, follow the separate preparation advice for that procedure.
What happens
There is usually no appointment for the test itself. The laboratory works on a sample of the cancer that has already been collected — either from a biopsy or from tissue removed during an operation. Sometimes a blood sample is taken instead or as well.
In the laboratory, scientists extract DNA, RNA or proteins from the sample and look for specific changes using methods such as immunohistochemistry, PCR or next-generation sequencing. The right test is chosen for the cancer type and the question being asked.
Results are sent to your cancer team and usually discussed at a multidisciplinary team (MDT) meeting, where specialists decide how the findings affect your diagnosis and treatment options. Your oncologist then explains what the results mean for you. How long this takes varies, from a few days for a single marker to around three weeks for a large panel.
Is this test right for me?
A good consultation should explore whether it's the right choice for you now — including reasons to wait or consider something else.
May not be suitable if…
- When the result would not change the treatment plan for that cancer and stage.
- When there is too little usable tissue and a repeat biopsy is not safe or worthwhile.
- Broad profiling panels marketed direct to patients when no clinician will use the result.
- When an inherited-risk question is better answered by a proper germline test with genetic counselling.
- When urgent treatment is needed and waiting for a complex panel would cause harmful delay.
Delay or rearrange if…
- There is not yet a suitable sample and a biopsy is being arranged.
- The clinical question has not been agreed, so the right test cannot be chosen.
- A previous sample may still be usable and should be checked first to avoid an unnecessary biopsy.
- Genetic counselling is needed before an inherited-risk test is done.
- The result is unlikely to be ready in time to inform an urgent decision.
Alternatives to discuss
- Using tissue already removed at a previous biopsy or operation instead of a new sample.
- A blood test (liquid biopsy) when tissue is limited.
- Standard pathology and staging alone where molecular testing would not change management.
- A targeted single-gene test rather than a broad panel when only one marker matters.
- Referral for inherited (germline) genetic testing with counselling where family risk is the question.
Before you decide
Use this as a shared-decision checklist. The aim is not just “can this be done?”, but whether it is right for you, now, with the risks and alternatives clearly understood.
What matters most to me?
Think about symptoms, daily life, work, caring responsibilities, sport, fertility, travel, appearance and anxiety — the right choice depends on your priorities, not just the medical facts.
What are all my options?
Ask about waiting, monitoring, medicines, rehabilitation, a smaller or larger procedure, a different test, NHS referral, or a second opinion where that would help.
What would make me pause?
Active infection, pregnancy, unstable medical problems, smoking, medicines that increase bleeding, poor support at home, or feeling pressured are all reasons to slow down and get tailored advice.
What happens if I do nothing today?
For some problems, waiting is safe; for others, delay can make treatment harder. A good consultation should explain the trade-off in plain English.
Benefits
- Can confirm or refine exactly what type of cancer you have.
- Can show whether a targeted drug or immunotherapy is likely to help — and spare you treatments unlikely to work.
- Can sometimes help estimate the chance of the cancer returning and whether extra treatment adds benefit.
- May open access to clinical trials matched to your cancer's changes.
- Can occasionally flag an inherited risk that matters for you and your family, with proper counselling.
Risks & complications
- The need to wait for results, which can be an anxious time
- A result that does not change your treatment, or finds no targeted option
- Findings of uncertain meaning that cannot yet be acted on
- Sometimes needing a further biopsy if there is not enough usable tissue
- The test failing or being inconclusive, so it has to be repeated
- A false-negative result (a change present but not detected), especially with blood tests
- Finding a possible inherited risk that was not expected, raising questions for relatives
- Delay to starting treatment while waiting for a complex result
- An incidental finding unrelated to the current cancer that needs further investigation
- Distress or family implications from unexpected genetic information
The test itself does not harm you — the main issues are uncertainty and waiting. Results are not always clear-cut: there may not be enough tissue, the result may be inconclusive, or no useful target may be found, and a blood test can miss a change that tissue would show. The biggest practical question is what each possible result would actually change for your treatment. If a test might reveal an inherited risk, ask in advance what support and counselling would follow.
Published figures to discuss
The test does not carry physical risk, but it is not perfect. Performance depends on the test used, the amount and quality of the sample, and the cancer type. Some samples have too little tumour to test; some results are inconclusive; and blood-based tests can miss changes that tissue would show (false negatives). Published figures vary widely by setting and cancer, so they are best discussed for your specific test rather than quoted as a single number; we have not stated rates here to avoid implying false precision.
| Figure | Reported range | How to interpret it | Source / confidence |
|---|---|---|---|
| Insufficient tumour sample | Common practical limitation | Small biopsies or low tumour content can fail testing and may require repeat biopsy or blood-based testing if appropriate. | Guide sourcesClinical context |
| Actionable mutation not found | Cancer- and panel-dependent | A negative result does not mean there are no treatments; it means no tested actionable alteration was found. | Guide sourcesClinical context |
| Germline implication discovered | Possible with some results | Some tumour findings may suggest inherited risk and need genetics referral. | Molecular Pathology of Cancer review — PMCncbi.nlm.nih.govSource-linked context |
| Treatment delayed while waiting for results | Clinical balancing issue | Teams balance urgency against the value of waiting for a result that could change treatment. | Guide sourcesClinical context |
These are literature figures, not a personalised prediction. Your own risks and likely benefits depend on your circumstances, your health, and how your care is carried out and followed up.
What happens afterwards
There is no physical recovery from the test itself. What matters afterwards is understanding the result, what it means for your treatment, and what to do if it is unclear. If a biopsy was needed to get the sample, that procedure has its own recovery advice.
- No physical after-effects from the test itself
- A period of waiting for results that many people find stressful
- A clinic appointment to talk through what the results mean
- Sometimes needing a repeat test or further biopsy
- Soreness only if a new biopsy was taken (see that procedure's advice)
Aftercare
- Make sure you have an appointment to discuss the results, not just a copy of the report.
- Ask your oncologist to explain in plain language what each finding means for your treatment.
- Keep a copy of the result to share with other clinicians, including your GP.
- If an inherited risk is raised, follow up the offer of genetic counselling.
- Ask what happens next if the result is inconclusive or needs repeating.
- If you had a biopsy to get the sample, follow that procedure's aftercare advice.
- Date and method of any biopsy already done
- A note of which test is being done and what it is for
- An appointment booked to discuss the results
- Questions written down about what each result would change
- Your GP's details so results can be shared
- A way to ask questions while you wait for results
⚠ Get urgent help if…
- Severe distress or inability to cope while waiting for results — tell your team, who can offer support
- If a biopsy was taken to get the sample: increasing pain, bleeding, fever or signs of infection at the biopsy site
- A long, unexplained delay in getting results that could hold up treatment — chase this with your team
- Being offered treatment based on a molecular result without a clear MDT discussion or explanation
- Pressure to pay for a broad 'tumour profiling' test that no one can explain the purpose of
Who to contact: your clinician, clinic or test provider first (keep their number to hand). For urgent advice when you can't reach them, call NHS 111. In an emergency, call 999.
General guidance — it doesn't replace the specific advice your specialist gives you.
Results & realistic expectations
A result describes the genetic and molecular features of your cancer at the time the sample was taken. It may confirm the diagnosis, show whether a particular targeted drug or immunotherapy is likely to help, or help estimate the chance of the cancer returning. Sometimes it finds no change that can be acted on, which is still useful information.
A molecular result cannot, by itself, tell you that a treatment will work or predict exactly what will happen. Cancers can also change over time, so a result reflects that sample at that moment. The most useful question is: what will this result change about my care, and what happens if it is normal, abnormal or inconclusive?
A molecular result reflects the cancer at the time of testing. As cancers can change, particularly after treatment, repeat testing on a new sample or a blood test is sometimes needed later — for example if the cancer progresses or stops responding. Your team will advise if and when retesting is worthwhile.
Related tests, treatments or support
Molecular testing is usually done alongside standard tests such as scans and the pathologist's examination of the tissue. Protein markers and gene tests are often reported together. The combined picture, discussed at an MDT, is what guides treatment — molecular results are interpreted in context, not in isolation.
Follow-up & long-term care
Once results are available, they are discussed at an MDT and explained to you by your oncologist, who links them to your treatment plan. If an inherited risk is suggested, you may be referred for genetic counselling. If the test is inconclusive, your team will explain whether a repeat or different test is needed. Results should be shared with your GP and any NHS or private teams involved.
- Repeat or additional testing if the cancer changes or stops responding to treatment
- Keeping records of results so they are available to all teams involved
- Genetic counselling follow-up if an inherited risk was found
- Reviewing eligibility for new targeted treatments or trials as evidence develops
Repeat, follow-on and what comes next
- If a sample is inadequate, the test may need repeating or a further biopsy may be advised.
- Inconclusive or uncertain results sometimes need a different or broader test.
- Because cancers can change, retesting on a new sample is sometimes needed later, for example if the cancer progresses.
- A blood test that is negative may still be followed by tissue testing to be sure.
Ask what happens if the result is unclear or needs repeating, and what is included if further tests or follow-up are needed.
What good aftercare looks like
- A clinic appointment where an oncologist explains the result and what it changes.
- A clear plan if the result is inconclusive, including repeat or alternative testing.
- Referral to genetic counselling if an inherited risk is identified.
- Results shared with the GP and all teams, including any NHS team.
- An honest account of what the result can and cannot tell you.
What affects the cost
Costs vary a great deal between people and providers, and we don't publish prices. What matters is understanding what drives the cost and making sure your quote is complete. The main things that affect it:
- The type of test — a single marker, a large gene panel or a blood-based test
- Whether a new biopsy is needed to obtain a suitable sample
- Laboratory and specialist reporting fees
- How quickly results are needed
- Discussion at a multidisciplinary team meeting and a clinic appointment to explain results
- Any genetic counselling if an inherited risk is found
- Repeat testing if the first sample is inadequate or inconclusive
- Exactly which test is being done and what it is looking for
- Whether a biopsy is included and its separate cost
- Laboratory and reporting fees
- A consultation to explain the results, not just a written report
- What happens, and any extra cost, if the sample is inadequate or the result inconclusive
- Whether genetic counselling is included if an inherited risk is found
- How results will be shared with your NHS team and GP
On the NHS? Many tumour molecular tests are funded by the NHS through the National Genomic Test Directory when clinically indicated; private testing is sometimes used for speed or for broader panels, but is only worthwhile if the result will change your care.
You're entitled to your total cost in writing — including reports, follow-up and what happens if the result is inconclusive — before you decide.
Consent traps and marketing red flags
These are not small details. They are often where patients lose choice, time to reflect, or realistic expectations.
Consent traps
- Not explaining whether the test is somatic (the cancer) or germline (inherited) and the different implications.
- Not discussing the chance of an inconclusive result or no actionable finding.
- No plan for who explains the result and what it will change.
- Not addressing what happens to the sample and data, including research use.
- Selling broad profiling without explaining that the result may not be usable.
Marketing red flags
- Direct-to-patient 'tumour profiling' promising to find a treatment for any cancer.
- Claims that a test can predict survival or guarantee that a treatment will work.
- Pressure to pay for broad panels without an MDT to interpret them.
- Blurring the line between inherited-risk testing and tumour testing.
- No discussion of false negatives, inconclusive results or sample limitations.
Choosing a specialist safely
- Check the specialist is on the GMC Specialist Register for this area.
- Make sure they work at a CQC-registered service, and look for membership of the relevant Royal College or professional body.
- You're entitled to time to consider and to have your questions answered before you agree — the specialist who looks after you should explain it, not a salesperson.
- Be wary of pressure: time-limited offers or deposits taken before you've had time to think are red flags, not bargains.
- You're entitled to your total cost in writing — including any follow-up — before you decide.
Questions to ask your medical professional
Take this to your consultation. A good specialist will welcome every one of these.
- What is this test looking for, and which treatment decision will it inform?
- Can you use tissue I already have, or do I need a new biopsy or a blood test?
- What happens if the result is normal, abnormal or inconclusive?
- How long will the result take, and will it delay starting treatment?
- Could this reveal an inherited risk, and what support would follow if it does?
- Is this test NHS-funded, and if I pay privately, will the result change my care?
- Are you on the GMC Specialist Register for this area, and which Royal College or professional body are you a member of?
- Will you be the specialist who carries out my test, and who looks after me afterwards?
- What are the risks for someone like me, and how often do your own patients have a problem or need it repeated or redone?
- What does a realistic result look like — and what can this test not achieve?
- What are my options, including waiting, doing nothing for now, or choosing a different approach?
- Can I have written information, results and aftercare instructions in a format I can use, including any accessibility or communication support I need?
- What is the total cost in writing, including any follow-ups, and how much time do I have to decide?
Frequently asked questions
Is this the same as a test for inherited cancer risk?
Will the result tell me my treatment will work?
Do I need another biopsy?
How long do results take?
Can I pay privately for broad tumour profiling?
What if no useful change is found?
Find a verified specialist for tumour genetic / molecular testing
Every consultant is GMC-checked and independently reviewed. Search by postcode and distance, or switch to a map. Ordered by rating, relevance and recency — never by who pays.
No verified consultants list this procedure yet — browse the full directory.
How we made this page
Medically reviewed by a GMC-registered consultant. Written in plain English, checked against NHS, NICE, GMC and relevant Royal College / specialist-society guidance, and kept under review. No clinic paid to appear on this page, and we publish no pricing. This is general information to help you prepare — it is not a substitute for advice from your own clinician. How we review our guides →
Source hierarchy: UK regulator and NHS/NICE guidance first, then relevant Royal College or specialist-society guidance, then peer-reviewed evidence for procedure-specific figures where available.
Sources & standards: NHS Genomics Education — Mainstreaming cancer gene testing (knowledge hub) NHS England — Genetic test to select best cancer treatment Cancer Research UK — Tests on your breast cancer cells (genes) NICE — Caris Molecular Intelligence (medtech advice) Molecular Pathology of Cancer review — PMC Cancer biomarker testing in England: pathologist survey — PMC
Reviews reflect patients' experience of care, not clinical outcomes. For procedure volumes and outcome data see PHIN.
Last medically reviewed 2026-09-21. Spotted something wrong or out of date? Report an error in this guide.
Related guides: Prostate biopsy · Breast biopsy · Lung cancer diagnosis and staging · Breast cancer treatment · Lung cancer treatment